Michael L. LeBlanc
Affiliations: | University of Washington, Seattle, Seattle, WA |
Area:
Statistics, Biostatistics BiologyGoogle:
"Michael LeBlanc"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Persky DO, Li H, Stephens DM, et al. (2020) Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000999 |
| Ha CS, LeBlanc M, Schöder H, et al. (2020) Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia & Lymphoma. 1-6 |
| Dai JY, LeBlanc M. (2019) Case-only trees and random forests for exploring genotype-specific treatment effects in randomized clinical trials with dichotomous endpoints. Journal of the Royal Statistical Society. Series C, Applied Statistics. 68: 1371-1391 |
| Kamdar M, Li H, Chen RW, et al. (2019) Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Advances. 3: 3132-3135 |
| Zhao YQ, LeBlanc ML. (2019) Designing precision medicine trials to yield greater population impact. Biometrics |
| Zhao YQ, Redman MW, LeBlanc ML. (2019) Quantifying treatment effects using the personalized chance of longer survival. Statistics in Medicine |
| Zhao YQ, Zeng D, Tangen CM, et al. (2019) Robustifying Trial-Derived Optimal Treatment Rules for A Target Population. Electronic Journal of Statistics. 13: 1717-1743 |
| Unger JM, Blanke CD, LeBlanc ML, et al. (2019) Patients enrolled in clinical trials with Medicaid or no insurance and overall survival benefits from new interventions. Journal of Clinical Oncology. 37: 119-119 |
| Unger JM, Nghiem VT, Hershman DL, et al. (2019) The impact of NCI-sponsored network group clinical trials on guideline care and new drug indications. Journal of Clinical Oncology. 37: 6604-6604 |
| Unger JM, Vaidya R, Albain KS, et al. (2019) Sex differences in adverse event reporting in SWOG chemotherapy, biologic/immunotherapy, and targeted agent cancer clinical trials. Journal of Clinical Oncology. 37: 11588-11588 |